Skip to main content

Table 1 Clinical characteristics

From: A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation

Characteristics Value
Patients 38
Age, y  
   Median 41
   Range (11–68)
Sex  
   Male 22
   Female 16
Diagnosis  
   Acute leukemia 16
   Lymphoma 6
   Multiple myeloma 4
   Myelodyspastic syndrome 4
   Solid tumor 4
   Non neoplastic disorders 3
   Chronic lynphocytid leukemia 1
Acute GVHD  
   0–I 27
   II–IV 11
Total body irradiation  
   Yes 15
   No 23
Conditioning regimen  
   Standard 25
   Reduced intensity conditioning 13
Type of transplant  
   Related 30
   Unrelated 8
Hemopoietic reconstitution  
   Median days of PMN >0.5 × 109/L (range) 16 (11 – 41)
   Median days of PLTS >20 × 109/L (range) 15 (9 – 65)
   Median days of PLTS >50 × 109/L (range) 18 (11 – 88)
Source of stem cells  
   Peripheral blood 31
   Bone marrow 4
   Cord blood 3
Prophylaxis of aGVHD  
   CyA+MTX 25
   CyA+MMF 6
   CyA+PDN 4
   Other 3
CMV status (donor/recipient)  
   Positive/positive 26
   Negative/positive 10
   Positive/negative 2
Deaths 4
  1. GVHD: Graft versus host disease; CyA: Cyclosporin-A; MTX: Methotrexate; PDN: Prednisone; CMV: Cytomeglovirus. MMF: Micofenolate Mofetil; PMN: Peripheral Mononuclear cells; PLTS: Platelets